NRXP NRx Pharmaceuticals, Inc.
Healthcare$4.34+0.00%OpenMarket Cap: $75.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-7.53
P/S
24.27
EV/EBITDA
-1.62
DCF Value
$0.74
FCF Yield
-26.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.1%
Operating Margin
-749.7%
Net Margin
-1070.3%
ROE
107.7%
ROA
-206.2%
ROIC
133.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.1M | 25.5% | $-4.7M | $-1.4M | $— | — |
| Q4 null | $983.0K | 48.3% | $-4.6M | $360.0K | $— | — |
| FY null | $1.2M | 58.8% | $-16.2M | $-28.6M | $— | — |
| Q3 null | $242.0K | 43.0% | $-4.1M | $-5.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.7M | $-17.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.8M | $-5.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-3.6M | $-9.1M | $— | — |
| FY null | $0.00 | -Infinity% | $-19.7M | $-25.1M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-3.0M | $-1.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-7.0M | $-7.9M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-6.0M | $-6.5M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.4M | $-4.3M | $-0.05 | — |